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Case Reportsyellowish mass and its characteristic change of appearance
when submerged in water to a villous sea anemone–like
tumor suggests the diagnosis of papillary fibroelastoma.
However, the definitive diagnosis is confirmed by
histopathologic examinations after surgery.CONCLUSIONS
We present an exceptional case of a papillary fibroelas-
toma originating from the aortic wall of the noncoronary
sinus. The patient was successfully managed with a valve-
sparing procedure. No aortic regurgitation was detected
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implantation for failed bioprosthesisGino Gerosa, MD,a Augusto D’Onofrio, MD,a Chiara Tessari, MD,a Demetrio Pittarello, MD,b
Maurizio Rubino, MD,a and Andrea Colli, MD, PhD,a Padua, ItalyTranscatheter valve-in-valve replacement is a reliable ther-
apeutic option for degenerated bioprosthetic heart valves in
high-risk patients. Successful transfemoral and transapical
techniques have been described for aortic, mitral, and
pulmonary bioprostheses. To the best of our knowledge,
few cases of transcatheter valve-in-valve tricuspid valve
implantation have been reported.1-3
Van Garsse and colleagues1 described the deployment of
the prosthesis via the right internal jugular vein with
ventricular pacing under cardiopulmonary bypass (CPB)
support via peripheral cannulation. Weich and colleagues2
and Cerillo and colleagues3 delivered the device via the
right internal jugular vein without ventricular pacing.
Hon and colleagues4 and Cheung and colleagues5 deliv-
ered the transcatheter prosthesis via a right thoracotomy and
direct puncture of the right atrium. We present a case of an
‘‘open’’ transcatheter valve-in-valve replacement in a high-
risk patient who required conventional cardiac surgery for
severe dysfunction of the aortic, mitral, and tricuspid heartvalves with a high frailty of right-sided heart structures
because of twice passed tricuspid valve replacement.CLINICAL SUMMARY
The patient is a 66-year-old woman with rheumatic heart
disease who underwent tricuspid valve replacement with
a bioprosthesis (Hancock Medtronic, 27 mm; Medtronic
Inc, Minneapolis, Minn) at 25 years of age. She underwent
reoperation at 39 years of age, and the calcified tricuspid bi-
oprosthesis was replacedwith a new bioprosthesis (Hancock
Medtronic, 29 mm) plus mitral commissurotomy. Six years
later, she underwent percutaneous mitral valvuloplasty for
recurrence of mitral stenosis. At that time, oral anticoagula-
tion was begun for the onset of permanent atrial fibrillation.
During the past 4 years, her clinical condition worsened
with shortness of breath and several hospital admissions
for congestive heart failure despite optimal medical treat-
ment. Transthoracic echocardiography revealed normal
left ventricular systolic function, left and right atrium
dilatation, a calcified tricuspid bioprosthesis with moderate
stenosis (mean gradient 11 mm Hg), severe regurgitation,
moderate mitral valve stenosis (mean gradient, 6 mm Hg),
severe regurgitation, and moderate aortic valve stenosis
(valve area, 0.66 cm2/m2).
A decision was made to replace the tricuspid bioprosthe-
sis and the mitral and aortic valves. The European System
for Cardiac Operative Risk Evaluation I was 31.55%, and
European System for Cardiac Operative Risk Evaluation II
was 36.73%. The patient underwent conventional
cardiac surgery through a median resternotomy, CPB, andardiovascular Surgery c Volume 146, Number 1 e3
FIGURE 1. Surgical field. Open transcatheter tricuspid balloon expandable valve-in-valve implantation for failed bioprosthesis. A, Position of the Edwards
Sapien XT valve 29 mm crimped on the balloon of the transcatheter delivery system (Ascendra; Edwards Lifesciences, Irvine, Calif) through the failed
tricuspid bioprosthesis. B, Balloon inflation and valve positioning. C, Final result of valve-in-valve position.
Case Reportscardioplegic arrest. She received an aortic mechanical pros-
thesis (St Jude Regent size 19; St Jude Medical Inc, St Paul,
Minn), a biologicalmitral prosthesis (Biocor Epic size 31; St
Jude Medical Inc), a transcatheter valve-in-valve Edwards
Sapien XT (size 29; Edwards Lifesciences, Irvine, Calif)
in the tricuspid position (Figure 1), and a reconstruction of
the superior vena cava with a Dacron prosthesis (12 mm).
The Sapien XT prosthesis was mounted on the transapi-
cal delivery system (Ascendra; Edwards Lifesciences) in
a normal orientation and implanted under direct vision
inside the previously implanted tricuspid valve prosthesis
(Figure 1). The deployment was uneventful, and transeso-
phageal intraoperative echocardiography revealed a well-
anchored device with no paravalvular leaks. The mean
gradient across the valve was 3 mm Hg (Figure 2). CPBFIGURE 2. Live 3-dimensional transesophageal echocardiography. A, Adequ
sure of the tricuspid valve-in-valve bioprosthesis. C, Color Doppler showing a
without paravalvular leaks. D, Postprocedure pulsatile Doppler of the tricuspid
e4 The Journal of Thoracic and Cardiovascular Surgetime was 420 minutes, and aortic crossclamp time was
194 minutes.
DISCUSSION
We present the first successful open surgery under
direct vision tricuspid valve-in-valve implantation. The
decision to implant the transcatheter prosthesis via
open surgery was made because of the presence of
a particular frail right atrium and superior vena cava
that required reconstruction with a Dacron prosthesis
and a consequent frail tricuspid annulus that made
third-time conventional replacement technically chal-
lenging and at high risk of late paravalvular leak. The
device was slowly deployed under direct vision with
partial inflation of the inner balloon to stabilize the valve.ate opening of the tricuspid valve-in-valve bioprosthesis. B, Adequate clo-
dequate position and function of the tricuspid valve-in-valve bioprosthesis
valve-in-valve bioprosthesis confirming a normal hemodynamic pattern.
ry c July 2013
Case ReportsAt this point, full inflation of the balloon was performed
with good expansion and anchoring of the device. Further
development of shorter-delivery catheters will facilitate
this intervention.
CONCLUSIONS
This patient presented a special combination of surgical
challenging problems, and it is unlikely that this approach
will becomewidely used; however, if indicated, the approach
is feasible and reproducible, and provides reliable results.From the Department of Thoracic and Vascular Surgery and Heart-Lung Transplan-
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valve technique. J Card Surg. 2012;27:196-8.Endovascular closure of Potts shunt before double lung
transplantation for idiopathic pulmonary arterial hypertensionMarina Paradela, MD, Olaf Mercier, MD, PhD, Alban Baruteau, MD, and Elie Fadel, MD, PhD,
Le Plessis-Robinson, FrancePotts shunt has been performed in children with severe
idiopathic pulmonary arterial hypertension (iPAH) as
a palliative treatment of right ventricular failure.1 This
procedure consists of a direct side-to-side anastomosis be-
tween the left pulmonary artery and the descending aorta.
It creates a similar hemodynamic condition to Eisen-
menger’s syndrome with an immediate clinical improve-
ment, but the disease process is unaffected. Indeed, lung
or heart-lung transplantations remain the ultimate treat-
ment if the condition worsens.2,3 Before transplantation,
closure of the Potts anastomosis is required to allow the
surgical procedure. We report a case of iPAH treated by
Potts shunt that had been closed with an aortic
endovascular stent-graft before double lung transplanta-
tion (DLTx).CLINICAL SUMMARY
A 14-year-old girl with a history of iPAH was referred to
the Marie Lannelongue Hospital for DLTx. She was diag-
nosed at 6 years of age and initially treated with bosentan
and epoprostenol. Two years later, she presented witha dyspnea New York Heart Association (NYHA)/World
Health Organization (WHO) functional class IV. She was
treated using a Potts shunt through a left thoracotomy with-
out cardiopulmonary bypass (CPB). The patient recovered
NYHA/WHO functional class II and was weaned from
epoprostenol.
Six years later, an episode of massive hemoptysis
developed in the patient. A thoracic contrast-enhancedFIGURE 1. Thoracic computed tomography showing the patent Potts
shunt, ascending aorta, descending aorta, and left pulmonary artery.
AAo, Ascending aorta; LPA, left pulmonary artery; DAo, descending aorta.
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